Jennifer Woyach, MD, The Ohio State University, Columbus, OH, presents an update on a Phase I trial of rocrutinib (NCT04775745), a novel fourth-generation covalent and non-covalent BTK inhibitor, which is being investigated in patients with relapsed/refractory (R/R) B-cell malignancies. In the cohort of patients with chronic lymphocytic leukemia (CLL), rocbrutinib is well-tolerated and has demonstrated an encouraging response rate of over 70%, with many patients remaining on treatment for two or more years. Promising results were also observed in patients with gatekeeper mutations who commonly develop resistance to pirtobrutinib. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.